California State Teachers Retirement System Sells 77,660 Shares of Bristol Myers Squibb Company $BMY

California State Teachers Retirement System reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 2.3% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 3,317,201 shares of the biopharmaceutical company’s stock after selling 77,660 shares during the period. California State Teachers Retirement System’s holdings in Bristol Myers Squibb were worth $201,188,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares during the period. United Bank grew its position in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares in the last quarter. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb during the second quarter worth about $221,000. Finally, Nebula Research & Development LLC bought a new position in Bristol Myers Squibb during the second quarter valued at about $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on BMY. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings lowered shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.25.

Bristol Myers Squibb Trading Up 1.7%

Shares of BMY opened at $63.65 on Wednesday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $64.96. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The stock has a 50 day simple moving average of $57.70 and a 200-day simple moving average of $58.17. The stock has a market cap of $129.97 billion, a PE ratio of 17.88, a PEG ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.